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Patients with sepsis display increased concentrations of sTREM-1 (soluble Triggering Re-
ceptor Expressed on Myeloid cells 1), and a phase II clinical trial focusing on TREM-1 mod-
ulation is ongoing. We investigated whether sTREM-1 circulating concentrations are as-
sociated with the outcome of patients with coronavirus disease 2019 (COVID-19) to as-
sess the role of this pathway in COVID-19. This observational study was performed in
two independent cohorts of patients with COVID-19. Plasma concentrations of sTREM-1
were assessed after ICU admission (pilot cohort) or after COVID-19 diagnosis (validation
cohort). Routine laboratory and clinical parameters were collected from electronic patient
files. Results showed sTREM-1 plasma concentrations were significantly elevated in pa-
tients with COVID-19 (161 [129–196] pg/ml) compared to healthy controls (104 [75–124]
pg/ml; P<0.001). Patients with severe COVID-19 needing ICU admission displayed even
higher sTREM-1 concentrations compared to less severely ill COVID-19 patients receiving
clinical ward-based care (235 [176–319] pg/ml and 195 [139–283] pg/ml, respectively, P =
0.017). In addition, higher sTREM-1 plasma concentrations were observed in patients who
did not survive the infection (326 [207–445] pg/ml) compared to survivors (199 [142–278]
pg/ml, P<0.001). Survival analyses indicated that patients with higher sTREM-1 concentra-
tions are at higher risk for death (hazard ratio = 3.3, 95%CI: 1.4–7.8). In conclusion, plasma
sTREM-1 concentrations are elevated in patients with COVID-19, relate to disease sever-
ity, and discriminate between survivors and non-survivors. This suggests that the TREM-1
pathway is involved in the inflammatory reaction and the disease course of COVID-19, and
therefore may be considered as a therapeutic target in severely ill patients with COVID-19.
Introduction
The current coronavirus disease 2019 (COVID-19) pandemic has, to date, led to almost three million
deaths (World Health Organization [WHO]) and caused massive societal and economic disruption. Se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19,
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can cause a variety of symptoms ranging from mild upper respiratory tract illness with no need for hospital ad-
mission to acute respiratory distress syndrome (ARDS) requiring admission to the hospital’s Intensive Care Unit
(ICU) [1, 2]. To identify patients with an unfavourable disease course, previous research has focused on biomarkers
for COVID-19 prognosis and showed a relationship between disease severity and elevated plasma concentrations of
C-reactive protein (CRP), D-dimer, and several inflammatory cytokines, especially interleukin (IL)-6 [2–5]. However,
it remains challenging to predict the prognosis early in the disease course of COVID-19, and more specific biomark-
ers are needed. In addition, elucidating the pathophysiological mechanisms could pave the way for identifying novel
therapeutic targets and new host-directed therapies [6, 7].
One pathway extensively investigated in sepsis and other acute and chronic inflammatory conditions is Trigger-
ing Receptor Expressed on Myeloid cells 1 (TREM-1). TREM-1 is an immunoglobulin-like receptor expressed by
innate immune cells that is known to amplify the innate immune response. Research has established that TREM-1 is
up-regulated in bacterial, viral and fungal infections, with release of the cell surface portion of the TREM-1 receptor,
soluble TREM-1 (sTREM-1) into the blood following activation of the receptor [8]. A meta-analysis of the studies
published on the diagnostic and prognostic value of sTREM-1 in sepsis demonstrated a clear correlation between
increased sTREM-1 plasma concentrations and mortality [9]. In a first publication on sTREM-1 in COVID-19, Van
Singer et al. reported a relationship between increased sTREM-1 plasma concentrations, disease severity and clinical
outcomes such as intubation and oxygen requirement [10].
In addition to the use of sTREM-1 as a prognostic biomarker, research has focused on modulation of the TREM-1
pathway. First, studies in mice show a favourable effect of transgenic or pharmacological TREM-1 modulation on
sepsis survival [11, 12]. In a recent phase IIa study, patients with septic shock were treated with nangibotide, a specific
TREM-1 modulator [13], demonstrating its safety and displaying trends towards clinically relevant benefits following
administration. A phase IIb clinical trial in adults with septic shock is underway to explore this (NCT 04429334).
Whether the TREM-1 pathway has either diagnostic or therapeutic value in COVID-19 is not yet known. To assess
this, research on the use of sTREM-1 as a predictive biomarker for selection of patients for this treatment is warranted.
The present study aims to investigate the behaviour of sTREM-1 plasma concentrations in COVID-19 patients and its
relation to disease severity and clinical outcomes. Furthermore, we assess whether patients with COVID-19 could be
stratified based on sTREM-1 plasma concentrations and therefore could possibly benefit from anti-TREM-1-therapy.
Materials and methods
Study design and patients
Our retrospective study included two independent cohorts: a pilot cohort of 21 healthy volunteers and 24 patients
with COVID-19 admitted to the ICU of Centre Hospitalier Régional Universitaire de Nancy, France, and a validation
cohort of 192 patients with COVID-19 (both ICU and non-ICU) admitted to the Radboud University Medical Centre
(Radboudumc), Nijmegen, the Netherlands.
The pilot cohort consists of 24 adult patients diagnosed with COVID-19 according to WHO interim guidance and
admitted to the ICU between 15 March and 31 March 2020. All patients were positive for SARS-CoV-2 by polymerase
chain reaction (PCR) and were admitted to the ICU for ARDS. The present study was approved by the local ethics
committee (Saisine n◦196).
The validation cohort consists of patients with a PCR-proven or clinically diagnosed SARS-CoV-2 infection admit-
ted to the Radboudumc between 6 March and 15 April 2020. Clinical diagnosis of COVID-19 infection was defined
based on signs and symptoms, specific computed tomography (CT) findings according the Dutch COVID-19 Re-
porting and Data System (CO-RADS) classification [14], and final consensus of clinical experts. 95% (183/192) of
the COVID-19-diagnosed patients had a positive PCR at the time of diagnosis. The study protocol was approved by
the local ethics committee (CMO 2020 6344 and CMO 2016 2963). All patients or legal representatives were informed
about the study details and could decline to participate. Ethylenediaminetetraacetic acid (EDTA) plasma was collected
at the first routine blood withdrawal for laboratory testing after COVID-19 diagnosis in the hospital. For analysis,
patients were stratified into groups based on disease severity and mortality. We defined disease severity based on the
need for ICU admission during hospital stay: severe illness in patients requiring ICU admission and moderate illness
in patients for whom only ward based care was necessary. Ten patients were admitted to a non-ICU ward at time of
sampling, but needed ICU admission later during their hospital stay. We have classified these patients in the severe
illness group.
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Data collection
For the pilot cohort, medical records were collected and retrospectively analysed. Clinical data and laboratory results
of the validation cohort were collected from electronic patient files (EPIC, EPIC Systems Corporation, Verona, WI,
U.S.A.) and recorded in electronic Case Report Forms (Castor EDC, Amsterdam, the Netherlands). Values of white
blood cell (WBC) counts, lymphocyte counts, and plasma concentrations of C-reactive protein (CRP), ferritin, and
D-dimer were collected at the day of plasma sampling. Clinical outcomes (ICU admission, hospital length of stay
[LOS], ICU LOS, incidence of thromboembolic events [TEE], and mortality) were recorded until hospital discharge.
Measurements and assays
Venous blood was collected in EDTA tubes and subsequently centrifuged at 2954 g (3800 RPM) at room temperature
for 10 min. Plasma was collected and aliquoted before storage at −80◦C for further analysis. Concentrations of IL-6
were measured using enzyme-linked immunosorbent assays (ELISA, Quantikine®, R&D systems) according to the
manufacturer’s protocol, with a lower detection limit of 16 pg/ml. Plasma sTREM-1 concentrations were measured
using an analytically validated ELISA assay according to regulatory requirements (EMA 2011) using a commercially
available, research use only ELISA assay (Human TREM-1 Quantikine® ELISA kit, R&D Systems). This method was
validated with lower and upper limits of quantification of 34.2 and 2070 pg/ml, respectively. For routine analysis, each
analytical run contained three levels of quality control (QC) sample (low, mid and high), and each run is accepted if
standard curve and QC samples are within acceptance criteria. The analytical performances and acceptance criteria
of this method are summarized in Supplementary Table S1.
Statistical analysis
The obtained data were analysed using SPSS version 25.0 (IBM Corp., Armonk, NY, U.S.A.), GraphPad Prism ver-
sion 8.0 (GraphPad Software, Inc., San Diego, CA, U.S.A.), and MedCalc version 19.6.4 (MedCalc Software Ltd, Os-
tend, Belgium). Differences between groups were assessed by Mann–Whitney U tests for continuous variables and by
Fisher’s exact tests for categorical variables. Correlations between sTREM-1 and inflammatory parameters were as-
sessed by Spearman’s rank correlation tests. Linear regression analyses were used to assess the associations of sTREM-1
concentrations and symptom duration, hospital LOS, and ICU LOS. Receiver operating characteristic (ROC) anal-
yses were performed to assess the prognostic performance of several biomarkers by calculating the area under the
curve (AUC). The optimal cut-off values for the biomarkers was defined based on the maximal Youden’s J index
and used to assess differences in survival during hospital admission for high versus low biomarker concentrations
by Kaplan–Meier survival analysis. Hazard ratios were based on the log-rank (Mantel-Cox) test. A P-value <0.05
(two-tailed) was considered statistically significant.
Results
sTREM-1 circulating concentrations are higher in COVID-19 patients
sTREM-1 concentrations were first measured in a cohort of 24 patients with COVID-19 admitted to the ICU of Nancy
Hospital (Figure 1A). The characteristics of these patients are provided in Supplementary Table S2. This analysis
demonstrated significantly higher sTREM-1 plasma concentrations for patients compared to 21 healthy controls (HC:
104 [75–124] pg/ml versus COVID-19: 161 [129–196] pg/ml, P<0.001, Figure 1B).
Elevated sTREM-1 concentrations in patients with severe COVID-19
A total of 218 patients diagnosed with COVID-19 and admitted to the Radboudumc were assessed for study inclu-
sion (Figure 1C). Of these, 12 patients refused to participate. Moreover, 13 other patients were excluded because no
plasma sample was available from first routine blood sampling after COVID-19 diagnosis (baseline), and one patient
was excluded due to a measurement error. The final study population (n=192) was divided in groups based on disease
severity (moderate illness [n=119] and severe illness [n=73]) and outcome (survivors [n=166] and non-survivors
[n=26]). Table 1 shows the characteristics of these patients, divided in groups of different disease severity and mor-
tality. Severely ill patients had higher concentrations of inflammatory parameters (CRP, ferritin, and IL-6), a longer
hospital LOS (31 days versus 7 days, P<0.001), and a higher mortality rate (22% versus 8%, P = 0.010) compared to
the patients admitted to the clinical wards. Non-survivors were older than survivors (73 versus 64 years, P<0.001)
and were more frequently admitted to the ICU (62% versus 34%, P = 0.010). No other relevant differences in gender,
BMI, and comorbidities were observed between the groups.
Figure 2 demonstrates higher sTREM-1 plasma concentrations in severely ill patients compared to patients with
moderate illness (Figure 2A, 235 [176-319] pg/ml versus 195 [139–283] pg/ml, P=0.017). Similarly, non-survivors
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 1. Study outline and results of the pilot cohort
Pilot cohort (A) flow chart and (B) sTREM-1 plasma concentrations for HC versus COVID-19 patients. (C) Flow chart of validation
cohort. Severe illness was defined as the need for ICU admission during hospital stay. Data are presented as median with interquar-
tile range. P-value was calculated with Mann–Whitney U test. ***: P<0.001. Abbreviations: COVID-19, coronavirus disease 2019;
sTREM-1, soluble Triggering Receptor Expressed on Myeloid cells 1; HC, healthy controls.
had higher sTREM-1 plasma concentrations compared to survivors (Figure 2B, 326 [207–445] pg/ml versus 199
[142–278] pg/ml, P<0.001). Furthermore, patients who developed thromboembolic events (n=28, 14%) presented
with increased sTREM-1 concentrations compared to patients without this complication (Figure 2C, 241 [199–309]
pg/ml versus 201 [142–292] pg/ml, P=0.044). Thromboembolic events encompassed pulmonary embolism (n=26),
cerebrovascular accident (n=2), and deep venous thrombosis (n=1). The relationship between sTREM-1 and dis-
ease severity or mortality was separately assessed in these subgroups, indicating the largest difference in sTREM-1
concentrations between survivors versus non-survivors (Supplementary Figure S1). Additionally, sTREM-1 base-
line concentrations were not associated with the total duration of hospital stay and ICU stay (Supplementary Figure
S2BC, R2 = 0.019, P=0.057 and R2 = 0.006, P=0.506, respectively) and sTREM-1 concentrations were indepen-
dent of symptom duration at time of sampling (R2 = 0.002, P=0.535, Supplementary Figure S2A). The latter finding
suggests that sTREM-1 is persistently increased during the disease course in COVID-19 patients, but longitudinal
measurements are warranted to prove this in future studies.
Significant correlations were observed for sTREM-1 concentration and WBC count, lymphocyte count, CRP, fer-
ritin, D-dimer, and IL-6 (Supplementary Figure S3A–F). These findings indicate that sTREM-1 concentrations are
directly associated with a systemic inflammatory response, although the increase in sTREM-1 concentrations is not
fully determined by the classical inflammatory markers.
Discriminatory power of sTREM-1 on mortality
Figure 3A presents the ROC-curve for discrimination between survivors and non-survivors based on sTREM-1 con-
4 © 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Age (years) 65 (54–72) 66 (53–73) 64 (57–71) 0.285 64 (53–71) 73 (69–75) <0.001
Sex (n, %)
Male 133 (69) 79 (66) 54 (74) 0.334 115 (69) 18 (69) 1.000
Female 59 (31) 40 (34) 19 (26) 51 (31) 8 (31)
BMI (kg/m2) 26.4 (24.0–29.0) 26.0 (23.7–28.9) 26.8 (24.7–29.3) 0.250 26.6 (23.9–29.3) 25.8 (24.0–28.4) 0.651
Comorbidity (n, %)
Diabetes mellitus 38 (20) 22 (19) 16 (22) 0.580 33 (20) 5 (19) 1.000
Cardiovascular disease 102 (53) 64 (54) 38 (52) 0.882 84 (51) 18 (69) 0.092
Pulmonary disease 39 (20) 31 (26) 8 (11) 0.016 31 (19) 8 (31) 0.188
Malignancy 48 (25) 34 (29) 14 (19) 0.171 41 (25) 7 (27) 0.810
Days of illness at day of
sampling (days)
11 (8–15) 10 (8–14) 13 (9–16) 0.022 11 (8–15) 11 (8–17) 0.882
ICU admission (n, %)1 73 (38) NA NA NA 57 (34) 16 (62) 0.010
Hospital length of stay (days) 9 (6–24) 7 (5–9) 31 (19–45) <0.001 9 (6–24) 15 (6–15) 0.339
Mortality (n,%) 26 (14) 10 (8) 16 (22) 0.010 NA NA NA
sTREM-1 (pg/ml) 208 (151–292) 195 (139–283) 235 (176–319) 0.017 199 (142–278) 326 (207–445) <0.001
CRP (mg/l) 109 (60–173) 81 (41–120) 175 (128–291) <0.001 103 (56–172) 139 (83–210) 0.154
Ferritin (μg/l) 1058 (543–1879) 822 (399–1461) 1694 (935–2554) <0.001 996 (491–1864) 1270 (717–1962) 0.237
IL-6 (pg/ml)2 72 (28–118) 43 (23–82) 144 (79–405) <0.001 67 (26–104) 188 (70–480) <0.001
Data are presented as median (IQR) or n (%). Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019; CRP, C-reactive
protein; ICU, intensive care unit; IL-6, interleukin-6; sTREM-1, soluble Triggering receptor Expressed on Myeloid cells 1.
1ICU admission during total hospital admission.
2measured in 151 of the 192 patients.
3moderate versus severe illness (Mann–Whitney U test).
4survivors versus non-survivors (Mann–Whitney U test).
centrations; the ROC-curves for CRP, ferritin and IL-6 are presented for comparison (Figure 3B–D). The test char-
acteristics of the ROC analyses are presented in Figure 3E. The AUC for sTREM-1 was 0.73 (95%CI: 0.62–0.83)
indicating moderate discrimination between survivors and non-survivors. This discriminatory power of sTREM-1
was similar to that of IL-6 (AUC = 0.77, 95%CI: 0.65–0.88; P=0.887), but performed better than CRP (AUC =
0.59, 95%CI: 0.47–0.72; P=0.132) and ferritin (AUC = 0.58, 95%CI: 0.46–0.70; P=0.078), although not significantly
different. Next, patient survival analysis stratified for sTREM-1 indicates that patients with sTREM-1 plasma concen-
trations of more than 315 pg/ml had an increased risk for in-hospital mortality (hazard ratio = 3.3, 95%CI: 1.4–7.8,
Figure 4A). Hazard ratios of mortality for high circulating concentrations of CRP, ferritin, and IL-6 were 1.2 (95%CI:
0.4–3.7), 1.9 (95%CI: 0.7–5.1), and 2.5 (95%CI: 0.9–6.9), respectively (Figure 4B–D). When combining the cut-off
values for both sTREM-1 and IL-6, the hazard ratio was 4.5 (95%CI: 1.1–18.9, Figure 4E), implying a synergistic
association between sTREM-1 and IL-6 in non-survivors.
Discussion
The results of our observational study validate the hypothesis that sTREM-1 concentrations are increased in patients
with COVID-19 and show that they are correlated with severity of the disease and subsequently with mortality. These
findings suggest that the TREM-1 pathway may play a role in the disease course in COVID-19, and is a potential target
for adjunctive immunotherapy.
Next to research into effective vaccines and potential antiviral drugs, numerous studies have focused on
host-directed strategies as an adjunctive approach to improve the outcome of COVID-19 patients [6, 15], especially
anti-inflammatory therapies such as anti-IL-6R antibodies or recombinant IL-1Ra. The beneficial impact of dex-
amethasone, acting most likely through its immune-modulating activities, on COVID-19 has been demonstrated
[16], and early findings of the REMAP-CAP trial reported a beneficial effect of anti-IL-6R therapy in patients with
COVID-19 admitted to the ICU [17]. However, not all patients respond favourably to these treatments and addi-
tional therapies are urgently needed. In the present study, we demonstrate that sTREM-1 circulating concentrations
are elevated in patients with COVID-19, and they are strongly correlated with mortality.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution











egen user on 18 O
ctober 2021
Bioscience Reports (2021) 41 BSR20210940
https://doi.org/10.1042/BSR20210940
Figure 2. sTREM-1 plasma concentrations in different groups of patients with COVID-19
sTREM-1 plasma concentration for (A) moderate and severely ill patients, (B) survivors and non-survivors, and (C) patients with and
without a TEE. Severe illness was defined as the need for ICU admission during hospital stay. Data are presented as median with
interquartile ranges. Exact P-values are 0.017 (A), <0.001 (B), 0.044 (C). P-values were calculated with Mann–Whitney U tests. *:
P<0.05, ***: P<0.001. Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit; sTREM-1, soluble triggering
receptor expressed on myeloid cells 1; TEE, thromboembolic event.
It is interesting to note that, regarding the subgroup analysis presented in Supplementary Figure S1, sTREM-1
concentrations are not different between moderate and severe illness in subgroups of survivors and non-survivors. It
could be suggested that patients with more severe illness are at higher risk of death and therefore there is an overlap
in the groups based on disease severity and mortality. When addressing this interaction, we observed that disease
severity alone does not result in different sTREM-1 plasma concentrations whereas, sTREM-1 plasma concentrations
6 © 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Cut-off Youden’s J Sensitivity Specificity PPV NPV
sTREM-1 >315 pg/mL 0.41 57.7% 83.7% 35.7% 92.7%
CRP >69 mg/L 0.21 86.4% 34.4% 17.1% 94.2%
Ferritin >665 μg/L 0.23 86.4% 36.2% 17.5% 94.4%






Figure 3. Discriminatory power for mortality in patients with COVID-19
Receiver-operating characteristic curves based on mortality for (A) sTREM-1, (B) CRP, (C) ferritin, and (D) IL-6 circulating concen-
trations and (E) the characteristics of these tests. Abbreviations: AUC, area under the curve; COVID-19, coronavirus disease 2019;
CRP, C-reactive protein; IL-6, interleukin-6; sTREM-1, soluble Triggering Receptor Expressed on Myeloid cells 1; NPV, negative
predictive value; PPV, positive predictive value.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. Survival analysis
Percentage of survival of patients with COVID-19 for high versus low concentrations of (A) sTREM-1, (B) CRP, (C) ferritin, (D)
IL-6, and (E) combination of sTREM-1 and IL-6. Cut-off values were based on the maximal Youden’s J index derived from the
receiver-operating characteristic curves (Figure 3). Hazard ratios were calculated with the log-rank (Mantel-Cox) test. Abbreviations:
COVID-19, coronavirus disease 2019; CRP, C-reactive protein; HR, hazard ratio; IL-6, interleukin-6; sTREM-1, soluble Triggering
Receptor Expressed on Myeloid cells 1.
8 © 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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are associated with mortality, independently of disease severity. Therefore, it can be concluded that the relationship
of sTREM-1 concentrations and mortality is most robust.
Our results are in line with a recent study showing significantly higher sTREM-1 concentrations in COVID-19
patients that required intubation or died, compared to patients who were admitted to the hospital and survived with-
out intubation [10]. Moreover, the authors report a good predictive accuracy of both sTREM-1 and IL-6 for disease
severity and mortality. Similarly, we have observed that the prognostic value of sTREM-1 is better than that of other
inflammatory markers such as CRP and ferritin, and similar to that of IL-6. sTREM-1 and IL-6 represent different as-
pects of the inflammatory response, but are both involved in the dysregulated inflammatory state seen in COVID-19
and sepsis patients. Therefore, we can speculate that a combination of these biomarkers could improve the iden-
tification of patients with an adverse outcome, which is also suggested by the results presented in Figure 4E. This
validates the proposal that combinations of sTREM-1 with other clinical parameters and biomarkers might improve
its prognostic potential, as shown previously in sepsis [9].
TREM-1 expression is upregulated following stimulation of human monocytes and neutrophils with various
Toll-like receptor (TLR) ligands, including those implicated in antiviral response (mainly TLR3, 7, 8, 9). Co-activation
of TREM-1 with these stimuli results in an increased production of cytokines [18–22]. Of note, coronaviruses are a
large family of single-stranded RNA (ssRNA) viruses, ssRNA being mainly recognized by TLR7/8. Activated TREM-1
amplifies inflammatory responses in a pathogen agnostic manner. First of all, it promotes immune cell responses ac-
tivated by the pattern recognition receptors (PRR). Moreover, TREM-1 activation was shown to result in a persistent
release of cytokines and chemokines (tumour necrosis factor alfa [TNF-α], IL-1β, IL-8, and monocyte chemotactic
protein [MCP]-1) [8], and is directly related to endothelial dysfunction [23] and platelet activation [24]. This might
suggest a link between TREM-1 activation and the increased incidence of thromboembolic events seen in COVID-19,
which is also supported by our data (Figure 2C). Because of the role of the TREM-1 pathway in the development of
a dysregulated inflammatory response in some patients, it is thought that the pathway could contribute to poor out-
comes in sepsis and COVID-19.
As studies in sepsis have indicated the TREM-1 pathway as a potential therapeutic target [11–13], it is tempting to
speculate that, like anti-IL-6R therapy, a beneficial effect of TREM-1 modulation in patients with COVID-19 could be
also present. Our data add to the hypothesis that anti-TREM-1 therapy could be effective in severely ill patients with
COVID-19. This is further advocated by the analogous associations of sTREM-1 and IL-6 with mortality presented in
the present study and the close relation of TREM-1 and IL-6 in the innate immune response to infections. A potential
advantage of TREM-1 modulation is the targeting of the initial immune dysregulation as TREM-1 is an amplifier of
the inflammatory response. Therefore, the immunosuppressive state reported in critically ill patients could potentially
be avoided [13, 25].
The mechanisms described above, and the strong correlation of sTREM-1 with mortality, suggest that inhibition of
TREM-1 may be beneficial in COVID-19. However, the timing of anti-inflammatory therapy in COVID-19 remains
challenging. Early application might not be necessary or could diminish an effective immune response, whereas in
advanced stages the hyperinflammation is already leading to adverse outcomes regardless of treatment [26]. As pro-
posed earlier in the sepsis field, patient selection for host-directed therapies based on clinical biomarkers is crucial
[27, 28]. sTREM-1 plasma concentrations might be useful for patient selection and follow-up of treatment effect and
therefore serve as a prognostic or predictive biomarker for anti-TREM-1 therapy [13].
This study also has some limitations. First, the study populations are relatively small, and we tried to compensate
for this by studying a discovery and validation cohort. Second, no longitudinal measurements of sTREM-1 plasma
concentrations during hospital admission were performed, and a comprehensive longitudinal analysis of the TREM-1
pathway in disease deterioration was therefore not possible. Therefore, direct conclusions regarding causality cannot
be drawn from our observational data and prospective studies are warranted. Third, a degree of variation in the
timepoint of baseline sample collection was introduced because of the pragmatic design of the present study during
the first wave of the pandemic; however, the differences in duration of symptoms or hospital stay at the time of
sampling do not seem to have significantly influenced the results.
In conclusion, the present study shows that sTREM-1 plasma concentrations are increased in patients
with COVID-19, and these concentrations are even higher in ICU patients and non-survivors. Moreover,
discrimination between survivors and non-survivors based on sTREM-1 plasma concentration was possi-
ble. Therefore, it could be speculated that TREM-1 inhibition is a therapeutic target in COVID-19, and
underlines the potential of a clinical trial of anti-TREM-1 treatment in patients with COVID-19, which is
underway.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Perspectives
• The TREM-1 pathway is known to amplify the inflammatory response in bacterial, viral, and fun-
gal infections, resulting in the release of sTREM-1 into the blood. In patients with sepsis, increased
sTREM-1 plasma concentrations are associated with mortality.
• sTREM-1 circulating concentrations are elevated in patients with COVID-19, especially in severely ill
patients. Moreover, sTREM-1 is able to discriminate between survivors and non-survivors.
• Our data suggest that the TREM-1 pathway is involved in the hyperinflammatory response and is
associated with adverse outcomes in COVID-19. Therefore, TREM-1 modulation might have clinical
benefits in patients with COVID-19.
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